The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72748
Title:
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Authors:
Olivier, Magali; Langerød, Anita; Carrieri, Patrizia; Bergh, Jonas; Klaar, Sigrid; Eyfjord, Jorunn; Theillet, Charles; Rodriguez, Carmen; Lidereau, Rosette; Bièche, Ivan; Varley, Jennifer; Bignon, Yves-Jean; Uhrhammer, Nancy; Winqvist, Robert; Jukkola-Vuorinen, Arja; Niederacher, Dieter; Kato, Shunsuke; Ishioka, Chikashi; Hainaut, Pierre; Børresen-Dale, Anne-Lise
Abstract:
To investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on 1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5 to 8 of TP53 by gene sequencing. TP53 mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype (high grade, large size, node positive cases, and low hormone receptor content) and in women <60 years old. TP53 mutations within exons 5 to 8 conferred an elevated risk of breast cancer-specific death of 2.27 (relative risk >10 years; P < 0.0001) compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status, and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179 and R248W) seem to be associated with an even worse prognosis. These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.
Affiliation:
IARC, Lyon, France.
Citation:
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. 2006, 12 (4):1157-67 Clin. Cancer Res.
Journal:
Clinical Cancer Research
Issue Date:
15-Feb-2006
URI:
http://hdl.handle.net/10541/72748
DOI:
10.1158/1078-0432.CCR-05-1029
PubMed ID:
16489069
Type:
Article
Language:
en
ISSN:
1078-0432
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorOlivier, Magali-
dc.contributor.authorLangerød, Anita-
dc.contributor.authorCarrieri, Patrizia-
dc.contributor.authorBergh, Jonas-
dc.contributor.authorKlaar, Sigrid-
dc.contributor.authorEyfjord, Jorunn-
dc.contributor.authorTheillet, Charles-
dc.contributor.authorRodriguez, Carmen-
dc.contributor.authorLidereau, Rosette-
dc.contributor.authorBièche, Ivan-
dc.contributor.authorVarley, Jennifer-
dc.contributor.authorBignon, Yves-Jean-
dc.contributor.authorUhrhammer, Nancy-
dc.contributor.authorWinqvist, Robert-
dc.contributor.authorJukkola-Vuorinen, Arja-
dc.contributor.authorNiederacher, Dieter-
dc.contributor.authorKato, Shunsuke-
dc.contributor.authorIshioka, Chikashi-
dc.contributor.authorHainaut, Pierre-
dc.contributor.authorBørresen-Dale, Anne-Lise-
dc.date.accessioned2009-07-07T12:01:13Z-
dc.date.available2009-07-07T12:01:13Z-
dc.date.issued2006-02-15-
dc.identifier.citationThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. 2006, 12 (4):1157-67 Clin. Cancer Res.en
dc.identifier.issn1078-0432-
dc.identifier.pmid16489069-
dc.identifier.doi10.1158/1078-0432.CCR-05-1029-
dc.identifier.urihttp://hdl.handle.net/10541/72748-
dc.description.abstractTo investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on 1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5 to 8 of TP53 by gene sequencing. TP53 mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype (high grade, large size, node positive cases, and low hormone receptor content) and in women <60 years old. TP53 mutations within exons 5 to 8 conferred an elevated risk of breast cancer-specific death of 2.27 (relative risk >10 years; P < 0.0001) compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status, and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179 and R248W) seem to be associated with an even worse prognosis. These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectTumour Suppressor Protein p53en
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDNA Mutational Analysis-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshMutation-
dc.subject.meshPrognosis-
dc.subject.meshSurvival Analysis-
dc.subject.meshSurvival Rate-
dc.subject.meshTumor Suppressor Protein p53-
dc.titleThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.en
dc.typeArticleen
dc.contributor.departmentIARC, Lyon, France.en
dc.identifier.journalClinical Cancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.